Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

This study is testing whether targeted radiation therapy (called SBRT) given after standard chemotherapy or immunotherapy can help control bladder cancer that has spread to a small number of sites in the body. **You may be eligible if...** - You are 18 or older - You have been diagnosed with bladder cancer (urothelial type) that has spread to lymph nodes or other parts of the body - You completed 4–6 cycles of first-line chemotherapy or immunotherapy for metastatic disease, and your cancer did not get worse during treatment - You have 3 or fewer remaining cancer spots visible on scans after treatment - Your cancer has not come back in your original surgical area (if you had your bladder removed) **You may NOT be eligible if...** - Your bladder cancer is a rare type (squamous cell, adenocarcinoma, or neuroendocrine) - You had brain or liver metastases before starting systemic treatment - You have had prior pelvic radiation that would prevent safe retreatment - You have active inflammatory bowel disease or a history of scleroderma - You have been diagnosed with another cancer in the past 5 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.